<SEC-DOCUMENT>0001640334-19-000577.txt : 20190412
<SEC-HEADER>0001640334-19-000577.hdr.sgml : 20190412
<ACCEPTANCE-DATETIME>20190412163802
ACCESSION NUMBER:		0001640334-19-000577
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190412
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190412
DATE AS OF CHANGE:		20190412

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Inmune Bio, Inc.
		CENTRAL INDEX KEY:			0001711754
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				475205835
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38793
		FILM NUMBER:		19746704

	BUSINESS ADDRESS:	
		STREET 1:		1224 PROSPECT STREET
		STREET 2:		SUITE 150
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
		BUSINESS PHONE:		8589643720

	MAIL ADDRESS:	
		STREET 1:		1224 PROSPECT STREET
		STREET 2:		SUITE 150
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>inmb_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<html><head><title>inmb_8k.htm</title><!--Document Created by EDGARMaster--></head><BODY spellcheck="true" style="text-align:justify;font:10pt TIMES NEW ROMAN;margin:0px 7%"><p style="MARGIN: 0px"> <table style="FONT-SIZE: 1px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td> <div style="HEIGHT: 4px; WIDTH: 100%; BACKGROUND: #000000; MARGIN: 0px 0px 2px" name="hrule"></div> <div style="HEIGHT: 2px; WIDTH: 100%; BACKGROUND: #000000" name="hrule"></div></td></tr></table></p> <p style="MARGIN: 0px" align="center">&nbsp;&nbsp;</p> <p style="MARGIN: 0px" align="center"><b><font size="3">UNITED STATES</font></b></p> <p style="MARGIN: 0px" align="center"><b><font size="3">SECURITIES AND EXCHANGE COMMISSION</font></b></p> <p style="MARGIN: 0px" align="center"><b><font size="3">Washington, D.C. 20549</font></b></p> <p style="MARGIN: 0px" align="center">&nbsp;</p> <p style="MARGIN: 0px" align="center"><b><font size="5">FORM 8-K</font></b></p> <p style="MARGIN: 0px" align="center">&nbsp;</p> <p style="MARGIN: 0px" align="center"><b>CURRENT REPORT</b></p> <p style="MARGIN: 0px" align="center">&nbsp;</p> <p style="MARGIN: 0px" align="center"><b>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></p> <p style="MARGIN: 0px" align="center">&nbsp;</p> <p style="MARGIN: 0px" align="center">Date of Report (Date of earliest event reported): <b>April 12</b> (<b>April 8, 2019</b>)</p> <p style="MARGIN: 0px">&nbsp;</p> <table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="55%" align="center" border="0"> <tr height="15"> <td style="BORDER-BOTTOM: 1px solid" valign="top"> <p style="MARGIN: 0px" align="center"><b><font size="5">INMUNE BIO INC.</font></b></p></td></tr> <tr height="15"> <td> <p style="MARGIN: 0px" align="center">(Exact name of registrant as specified in charter)</p></td></tr></table> <p style="MARGIN: 0px">&nbsp;</p> <table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="85%" align="center" border="0"> <tr height="15"> <td style="BORDER-BOTTOM: 1px solid" valign="top" width="30%"> <p style="MARGIN: 0px" align="center"><b>Nevada</b></p></td> <td valign="top" width="5%"> <p style="MARGIN: 0px" align="center">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid" valign="top" width="30%"> <p style="MARGIN: 0px" align="center"><b>001-38793</b></p></td> <td valign="top" width="5%"> <p style="MARGIN: 0px" align="center">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid" valign="top" width="30%"> <p style="MARGIN: 0px" align="center"><b>47-5205835</b></p></td></tr> <tr height="15"> <td valign="top"> <p style="MARGIN: 0px" align="center">(State or other jurisdiction</p></td> <td valign="top"> <p style="MARGIN: 0px" align="center">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px" align="center">(Commission</p></td> <td valign="top"> <p style="MARGIN: 0px" align="center">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px" align="center">(IRS Employer</p></td></tr> <tr height="15"> <td valign="top"> <p style="MARGIN: 0px" align="center">of incorporation)</p></td> <td valign="top"> <p style="MARGIN: 0px" align="center">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px" align="center">File Number)</p></td> <td valign="top"> <p style="MARGIN: 0px" align="center">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px" align="center">Identification No.)</p></td></tr></table> <p style="MARGIN: 0px" align="center">&nbsp;</p> <p style="MARGIN: 0px" align="center"><b><u>1224 Prospect Street, Suite 150, La Jolla, CA 92037</u></b></p> <p style="MARGIN: 0px" align="center">(Address of Principal Executive Offices) (Zip Code)</p> <p style="MARGIN: 0px" align="center">&nbsp;</p> <p style="MARGIN: 0px" align="center"><b><u>(858) 964 3720</u></b></p> <p style="MARGIN: 0px" align="center">(Registrant&#8217;s Telephone Number, Including Area Code)</p> <p style="MARGIN: 0px" align="center">&nbsp;</p> <p style="MARGIN: 0px" align="center"><b><u>Not Applicable</u></b></p> <p style="MARGIN: 0px" align="center">(Former Name or Former Address, If Changed Since Last Report)</p> <p style="MARGIN: 0px" align="center">&nbsp;</p> <p style="MARGIN: 0px" align="justify">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<u>see</u>&nbsp;General Instruction A.2. below):</p> <p style="MARGIN: 0px">&nbsp;</p> <table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr height="15"> <td width="4%"> <p style="MARGIN: 0px" align="justify">&nbsp;</p></td> <td valign="top" width="4%"> <p style="MARGIN: 0px" align="justify"><font face="Wingdings">&#168;</font></p></td> <td valign="top"> <p style="MARGIN: 0px" align="justify">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr> <tr height="15"> <td> <p style="MARGIN: 0px" align="justify">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px" align="justify"><font face="Wingdings">&#168;</font></p></td> <td valign="top"> <p style="MARGIN: 0px" align="justify">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr> <tr height="15"> <td> <p style="MARGIN: 0px" align="justify">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px" align="justify"><font face="Wingdings">&#168;</font></p></td> <td valign="top"> <p style="MARGIN: 0px" align="justify">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr> <tr height="15"> <td> <p style="MARGIN: 0px" align="justify">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px" align="justify"><font face="Wingdings">&#168;</font></p></td> <td valign="top"> <p style="MARGIN: 0px" align="justify">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="justify">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="justify">Emerging growth company <font style="FONT-FAMILY: Wingdings">x</font></p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="justify">If an emerging growth company, indicate by check mart if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <font style="FONT-FAMILY: Wingdings">&#168;</font></p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="justify"> <table style="FONT-SIZE: 1px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td> <div style="HEIGHT: 2px; WIDTH: 100%; BACKGROUND: #000000; MARGIN: 0px 0px 2px" name="hrule"></div> <div style="HEIGHT: 4px; WIDTH: 100%; BACKGROUND: #000000" name="hrule"></div></td></tr></table></p> <p style="MARGIN: 0px"> <table class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td class="hpbhr">&nbsp;</td></tr> <tr> <td>&nbsp;</td></tr> <tr> <td> <div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr> <tr> <td>&nbsp;</td></tr></table></p> <p style="MARGIN: 0px">&nbsp;&nbsp;</p> <p style="MARGIN: 0px" align="justify"><b>Item 8.01 Other Events </b></p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">On April 8, 2019, INmune Bio, Inc. (the &#8220;Company&#8221;) issued a press release (the &#8220;Release&#8221;) announcing that Lesley Probert, Ph.D., Head of Immunology Department at the Hellenic Pasteur Institute in Athens, Greece, will be presenting on the Company&#8217;s drug candidate XPro 1595 at the European Conference on Neuroinflammation on April 8 and 9, 2019. </p> <p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p> <p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">On April 9, 2019, the Company issued a press release (the &#8220;Second Release&#8221;) announcing that its Raymond J. Tesi, the Company&#8217;s Chief Executive Officer, will be presenting at Cambridge Healthtech Institute&#8217;s Inflammation Inhibitors Conference on April 11, 2019 in San Diego, California. </p> <p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p> <p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">A copy of the Release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and a copy of the Second Release is being furnished as Exhibit 99.2 to this Current Report on Form 8-K. Exhibits 99.1 and 99.2 shall not be deemed &#8220;filed&#8221; for purposed of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act. </p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="justify"><b>Item 9.01 Financial statements and Exhibits</b></p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="justify">(d) Exhibits.</p> <p style="MARGIN: 0px">&nbsp;</p> <table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr height="15"> <td style="BORDER-BOTTOM: 1px solid" valign="top" width="8%"> <p style="MARGIN: 0px" align="justify"><b>Exhibit</b></p> <p style="MARGIN: 0px" align="justify"><b>Number</b></p></td> <td valign="top" width="2%"> <p style="MARGIN: 0px" align="justify">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid" valign="bottom"> <p style="MARGIN: 0px" align="justify"><b>Description</b></p></td></tr> <tr height="15" bgcolor="#cceeff"> <td valign="top"> <p style="MARGIN: 0px" align="justify"><a href="inmb_ex991.htm">99.1</a></p></td> <td valign="top"> <p style="MARGIN: 0px" align="justify">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px" align="justify"><a href="inmb_ex991.htm">Greece Presentation Release dated April 8, 2019</a></p></td></tr> <tr height="15" bgcolor="#ffffff"> <td valign="top"> <p style="MARGIN: 0px" align="justify"><a href="inmb_ex992.htm">99.2</a></p></td> <td valign="top"> <p style="MARGIN: 0px" align="justify">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px" align="justify"><a href="inmb_ex992.htm">CEO Presentation Release dated April 9, 2019 </a></p></td></tr></table> <p style="MARGIN: 0px" align="left">&nbsp;</p> <p style="MARGIN: 0px" align="left"> <table id="pagebreak67179e2b-d429-4d6a-aa60-b6e310679249" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td class="hpbhr">&nbsp;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid"> <p style="MARGIN: 0px" align="center">2</p></td></tr> <tr> <td> <div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr> <tr> <td>&nbsp;</td></tr></table></p> <p style="MARGIN: 0px" align="center">&nbsp;&nbsp;</p> <p style="MARGIN: 0px" align="center"><b>SIGNATURE</b></p> <p style="MARGIN: 0px" align="center">&nbsp;</p> <p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p> <p style="MARGIN: 0px">&nbsp;</p> <table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr height="15"> <td valign="top"> <p style="MARGIN: 0px" align="justify">&nbsp;</p></td> <td valign="top" colspan="2"> <p style="MARGIN: 0px" align="justify"><b>INMUNE BIO INC.</b></p></td> <td></td></tr> <tr height="15"> <td valign="top"></td> <td valign="top" colspan="2"></td> <td> <p style="MARGIN: 0px" align="justify">&nbsp;</p></td></tr> <tr height="15"> <td valign="top" width="50%"> <p style="MARGIN: 0px" align="justify">Date: April 12, 2019</p></td> <td valign="top" width="3%"> <p style="MARGIN: 0px" align="justify">By:</p></td> <td style="BORDER-BOTTOM: 1px solid" valign="top" width="35%"> <p style="MARGIN: 0px" align="justify"><i>/s/ David Moss</i></p></td> <td width="12%"></td></tr> <tr height="15"> <td valign="top"></td> <td valign="top"> <p style="MARGIN: 0px" align="justify">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px" align="justify">David Moss</p></td> <td></td></tr> <tr height="15"> <td valign="top"></td> <td valign="top"> <p style="MARGIN: 0px" align="justify">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px" align="justify">Chief Financial Officer</p></td> <td></td></tr></table> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px" align="justify"> <table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cols="1" cellpadding="0" width="100%" align="center" border="0"> <tr> <td style="BORDER-BOTTOM: black 1px solid"> <p style="MARGIN: 0px" align="center">3</p></td></tr></table></p> <p style="MARGIN: 0px">&nbsp;</p></BODY><!--Document Created by EDGARMaster--></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>inmb_ex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head><title>inmb_ex991.htm</title><!--Document Created by EDGARMaster--></head><BODY spellcheck="true" style="text-align:justify;font:10pt TIMES NEW ROMAN;margin:0px 7%"><p style="MARGIN: 0px" align="right"><b>EXHIBIT 99.1</b></p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in" align="center"><b><font size="3">INmune Bio Announces Poster Presentation with New </font></b></p> <p style="MARGIN: 0px 0px 0px 0in" align="center"><b><font size="3">Data Regarding Neurodegenerative Disease Drug</font></b></p> <p style="MARGIN: 0px 0px 0px 0in" align="center"><b><font size="3">Candidate, XPro1595, at The European Conference on Neuroinflammation</font></b></p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in">LA JOLLA, Calif., April 08, 2019 (GLOBE NEWSWIRE) --&nbsp;INmune Bio, Inc.&nbsp;(NASDAQ:&nbsp;INMB), an immunology company focused on developing treatments that harness the patient&#8217;s innate immune system to fight disease, today announced that Lesley Probert, Ph.D., Head of Immunology Department at the&nbsp;&nbsp;Hellenic Pasteur Institute&nbsp;in Athens, Greece, will be presenting a poster about new data on the company&#8217;s neurodegenerative disease drug candidate XPro1595 at&nbsp;The European Conference on Neuroinflammation&nbsp;on April 8 and 9.</p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in">The poster presentation, titled &#8220;Selective inhibition of soluble TNF promotes macrophage phagocytosis of myelin debris and remyelination of demyelinated lesions&#8221;, is a follow up study of Dr. Probert&#8217;s&nbsp;earlier work&nbsp;demonstrating that XPro1595 promotes remyelination in animal models of Multiple Sclerosis. The current study sheds some light onto how XPro1595 does this. Dr. Probert found that XPro1595 may promotes remyelination by increasing the presence of immune cells that remove damaged myelin. &#8220;Clearing out the dead myelin is a key trigger for remyelination. We believe that inflammation, and particularly soluble tumor necrosis factor (<i>the target of XPro1595</i>), changes the function of macrophages, from cells that usually clear dead myelin, to inflammatory cells that perpetuate disease pathology,&#8221; says Dr. Probert.&nbsp;</p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in">Dr. Probert is one of the world&#8217;s leading experts on tumor necrosis factor (TNF) biology in the brain as it relates to myelin &#8211; the insulation around neurons that are key to making them work and the pathology associated with Multiple Sclerosis.</p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in">XPro1595 has been tested in multiple animal models of Multiple Sclerosis by a number of research groups in the US and Europe. &#8220;The work done by Dr. Probert and others with XPro1595 in the Multiple Sclerosis models is very impressive,&#8221; says Dr. CJ Barnum, the Director of Neuroscience for INmune Bio. &#8220; We look forward to seeing how their work advances and what this might mean for patients suffering from MS.&#8221;</p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in">The European Conference on Neuroinflammation &#8211; Basic and Clinical Concepts in association with The Oxford Centre for Neuroinflammation is the first in a series of annual events that will facilitate the investigative and analytical discussion of a range of neurodegenerative diseases.</p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px"> <table id="pagebreakf2a4031e-eb28-4131-9fa7-749ba214a939" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td class="hpbhr">&nbsp;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid">&nbsp;</td></tr> <tr> <td> <div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr> <tr> <td>&nbsp;</td></tr></table></p> <p style="MARGIN: 0px">&nbsp;&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in"><b>About XPro1595</b> </p> <p style="MARGIN: 0px 0px 0px 0in">XPro2595 is a novel biologic DN-TNF therapy that neutralizes soluble TNF without affecting trans-membrane TNF or TNF receptors.&nbsp; XPro1595 is entering a biomarker directed Phase I clinical trial in patients with mild-to-moderate Alzheimer&#8217;s disease who have biomarkers of neuroinflammation to determine if neutralizing soluble TNF can decrease those biomarkers neuroinflammation There can be no assurance that XPro1595 or any of the company&#8217;s other products will be granted approvals or that the data presented in the Poster Presentation will result in successful clinical trials.</p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in"><b>About INmune Bio, Inc.</b></p> <p style="MARGIN: 0px 0px 0px 0in">INmune Bio, Inc. is a publicly traded (NASDAQ: INMB) clinical-stage biotechnology company developing therapies targeting the innate immune system to fight disease. INmune Bio is developing three product platforms: two products that reengineer the patient&#8217;s innate immune system&#8217;s response to cancer and one product to treat neuroinflammation that is currently focused on Alzheimer&#8217;s disease. INKmune is a natural killer (NK) cell therapeutic that primes the patient&#8217;s NK cells to attack minimal residual disease, the remaining cancer cells that are difficult to detect, which often cause relapse. INB03 inhibits myeloid derived suppressor cells (MDSC), which often cause resistance to immunotherapy, such as anti-PD-1 checkpoint inhibitors. XPro1595 targets neuroinflammation, which causes microglial activation and neuronal cell death. INmune Bio&#8217;s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit&nbsp;www.inmunebio.com.</p> <p style="MARGIN: 0px">&nbsp;</p><b>Information about Forward-Looking Statements</b> <p style="MARGIN: 0px">Statements in this press release relating to our drug candidates and our ability to optimize our opportunities for growth and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.</p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px">This release contains &#8220;forward-looking statements&#8221; Forward-looking statements reflect our current view about future events. When used in this release, the words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;future,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward&#8211;looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize products and services; changes in government regulation; and other factors relating to our industry, our operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned. </p> <p style="MARGIN: 0px 0px 0px 0in">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in"> <table id="pagebreak738845db-4e76-4d9a-a4e4-d8e1c89943d3" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td class="hpbhr">&nbsp;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid">&nbsp;</td></tr> <tr> <td> <div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr> <tr> <td>&nbsp;</td></tr></table></p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in">Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements. For a more detailed description of the risk factors and uncertainties affecting the Company please refer to the Company&#8217;s recent Securities and change Commission filings, which are available at&nbsp;http://www.sec.gov/cgi-bin/browse-edgar?company=inmune&amp;owner=exclude&amp;action=getcompany.&nbsp; The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless otherwise required by law.</p> <p style="MARGIN: 0px">&nbsp;</p><b>INmune Bio Contact:&nbsp;</b> <p style="MARGIN: 0px">David Moss, CFO</p> <p style="MARGIN: 0px">(858) 964-3720</p>DMoss@INmuneBio.com&nbsp; <p style="MARGIN: 0px">&nbsp;</p><b>Media Contact:&nbsp;</b> <p style="MARGIN: 0px">Antenna Group</p> <p style="MARGIN: 0px">Sharon Golubchik</p> <p style="MARGIN: 0px">(201) 465-8008</p>INmuneBio@AntennaGroup.com <p style="MARGIN: 0px">&nbsp;</p><b>Investor Contact:&nbsp;</b> <p style="MARGIN: 0px">KCSA Strategic Communications</p> <p style="MARGIN: 0px">Valter Pinto / Scott Eckstein&nbsp;</p> <p style="MARGIN: 0px">PH: (212) 896-1254 / (212) 896-1210</p>INmune@KCSA.com <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px"> <table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cols="1" cellpadding="0" width="100%" align="center" border="0"> <tr> <td style="BORDER-BOTTOM: black 1px solid"> <p style="MARGIN: 0px" align="center">&nbsp;</p></td></tr></table></p> <p style="MARGIN: 0px">&nbsp;</p></BODY><!--Document Created by EDGARMaster--></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>inmb_ex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<html><head><title>inmb_ex992.htm</title><!--Document Created by EDGARMaster--></head><BODY spellcheck="true" style="text-align:justify;font:10pt TIMES NEW ROMAN;margin:0px 7%"><p style="MARGIN: 0px" align="right"><b>EXHIBIT 99.2</b></p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in" align="center"><b><font size="3">INmune Bio Co-Founder and CEO to Speak at Cambridge</font></b></p> <p style="MARGIN: 0px 0px 0px 0in" align="center"><b><font size="3">Healthtech Institute&#8217;s 10th Annual Inflammation Inhibitors Conference</font></b></p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in"><i>Presentation will focus on a therapeutic strategy to address the need for potent anti-inflammatory treatments that do not worsen immunosuppression</i></p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px">LA JOLLA, Calif., April 09, 2019 (GLOBE NEWSWIRE) --&nbsp;INmune Bio, Inc.&nbsp;(NASDAQ:&nbsp;INMB), an immunology company focused on developing treatments that harness the patient&#8217;s innate immune system to fight disease, today announced that RJ Tesi, M.D., the company&#8217;s co-founder and CEO, will be presenting at&nbsp;Cambridge Healthtech Institute&#8217;s Inflammation Inhibitors Conference&nbsp;on April 11 in San Diego.</p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px">&#8220;Inflammation, especially chronic inflammation, is being recognized as an important part of the pathophysiology of many diseases, including cancer and Alzheimer&#8217;s disease,&#8221; said Dr. Tesi. &#8220;Drugs targeting chronic inflammation must reverse innate immune system dysfunction without worsening immunosuppression caused by chronic inflammation.&#8221;</p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px">Dr. Tesi&#8217;s presentation on April 11 will address&nbsp;targeting soluble tumor necrosis factor (TNF) to eliminate chronic inflammation without immunosuppression. It will take place during the conference&#8217;s session covering how to target the innate immune system.</p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px">INB03, currently being tested in a Phase 1 clinical trial, is a selective inhibitor of soluble TNF that is a potent anti-inflammatory agent while not being immunosuppressive. INB03 is significantly different from currently approved non-selective TNF inhibitors that block both soluble TNF and transmembrane TNF; a difference that has implications for both safety and efficacy of the TNF targeted therapy.</p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px">Cambridge Healthtech Institute&#8217;s 10<sup>th</sup>&nbsp;Annual Inflammation Inhibitors conference brings together discovery chemists and biologists who work on immunology-related drug targets to learn from one another and stay abreast of the latest discovery and medicinal chemistry efforts in the field.</p> <p style="MARGIN: 0px">&nbsp;</p> <b>Details of Dr. Tesi&#8217;s presentation are as follows:</b> <p style="MARGIN: 0px">Session Title: Targeting the Innate Immune System</p> <p style="MARGIN: 0px">Presentation Title: Targeting Soluble TNF to Eliminate Chronic Inflammation without Immunosuppression</p> <p style="MARGIN: 0px">Date: April 11, 2019</p>Time: 4:50 p.m. <p style="MARGIN: 0px 0px 0px 0in">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in"> <table id="pagebreak7204da32-522c-4aa1-824b-2fe5bb6309dd" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td class="hpbhr">&nbsp;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid">&nbsp;</td></tr> <tr> <td> <div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr> <tr> <td>&nbsp;</td></tr></table></p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in"><b>About INmune Bio, Inc.</b></p> <p style="MARGIN: 0px 0px 0px 0in">INmune Bio, Inc. is a publicly traded (NASDAQ: INMB) clinical-stage biotechnology company developing therapies targeting the innate immune system to fight disease. INmune Bio is developing three product platforms: two products that reengineer the patient&#8217;s innate immune system&#8217;s response to cancer and one product to treat neuroinflammation that is currently focused on Alzheimer&#8217;s disease. INKmune is a natural killer (NK) cell therapeutic that primes the patient&#8217;s NK cells to attack minimal residual disease, the remaining cancer cells that are difficult to detect, which often cause relapse. INB03 inhibits myeloid derived suppressor cells (MDSC), which often cause resistance to immunotherapy, such as anti-PD-1 checkpoint inhibitors. XPro1595 targets neuroinflammation, which causes microglial activation and neuronal cell death. INmune Bio&#8217;s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit&nbsp;www.inmunebio.com.</p> <p style="MARGIN: 0px">&nbsp;</p> <b>INmune Bio Contact:&nbsp;</b> <p style="MARGIN: 0px">David Moss, CFO</p> <p style="MARGIN: 0px">(858) 964-3720</p>DMoss@INmuneBio.com &nbsp; <b>Media Contact:&nbsp;</b> <p style="MARGIN: 0px">Antenna Group</p> <p style="MARGIN: 0px">Sharon Golubchik</p> <p style="MARGIN: 0px">(201) 465-8008</p>INmuneBio@AntennaGroup.com&nbsp; <p style="MARGIN: 0px">&nbsp;&nbsp;</p> <p style="MARGIN: 0px"> <table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cols="1" cellpadding="0" width="100%" align="center" border="0"> <tr> <td style="BORDER-BOTTOM: black 1px solid"> <p style="MARGIN: 0px" align="center">&nbsp;</p></td></tr></table></p> <p style="MARGIN: 0px">&nbsp;</p></BODY><!--Document Created by EDGARMaster--></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
